Skip to main content
TipRanks
Go Ultimate75% OFF

Clearmind Medicine (CWY1) AI Stock Analysis

DE:CWY1

Clearmind Medicine

(Frankfurt:CWY1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Improved CapitalizationHigher equity and materially lower leverage provide a stronger financial foundation than in earlier periods. This reduces balance-sheet stress and may give the company more flexibility to fund research and advance its programs, although continued losses still limit that support.
Negative Factors
No Commercial RevenueThe absence of revenue confirms that Clearmind has not yet reached commercial scale and remains dependent on advancing development programs before generating operating income. This leaves the business exposed to long timelines between research spending and potential product monetization.

Clearmind Medicine (CWY1) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:CWY1-65.03%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.33M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.0
Beta (1Y)
0.32
Revenue Growth
―
EPS Growth
75.61%
Country
Germany
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Clearmind Medicine Business Overview & Revenue Model

Company Description

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lac...

Clearmind Medicine Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:CWY1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ENVBENVB48Neutral$6.31M-0.22-163.22%――93.45%
NEUPNEUP48Neutral$12.55M-2.75-18.55%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:CWY1ENVBSILOPBMNEUPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:CWY1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:CWY1Clearmind Medicine Inc.180.48-348.80-65.90%
ENVBEnveric Biosciences, Inc.1.35-4.41-76.56%
SILOSilo Pharma Inc1.71-4.68-73.24%
PBMPsyence Biomedical Ltd.2.97-6.47-68.53%
NEUPNeuphoria Therapeutics Inc.2.35-2.08-46.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.